Therapeutic Asset Ratings

197 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Bg-C0902 Neoplasm	BeOne Medicines	P1	C (37)
bi 1703880 Neoplasm	Boehringer Ingelheim	P1	C (37)
bi 1821736 Neoplasm	Boehringer Ingelheim	P1	C (37)
bi 1831169 Neoplasm	Boehringer Ingelheim	P1	C (37)
bi 3923948 Neoplasm	Boehringer Ingelheim	P1	C (37)
bi 770371 Neoplasm	Boehringer Ingelheim	P1	C (37)
Bl-Arc002 Neoplasm	Sichuan Baili Pharmaceutical Co., Ltd.	P1	C (37)
Budigalimab Neoplasm	AbbVie	P1	C (37)
Casdatifan Neoplasm	Arcus Biosciences, Inc.	P1	C (37)
Cba-1205 Neoplasm	Chiome Bioscience Inc.	P1	C (37)
Cba-1535 Neoplasm	Chiome Bioscience Inc.	P1	C (37)
cx-904 Neoplasm	CytomX Therapeutics	P1	C (37)
D-Ala-D-Ala-Leu-Pro-Ile-Pro-Leu-Asp-Gln-Thr-D-Ala-D-Ala-NH2 Neoplasm	SparX Biotech(Jiangsu) Co., Ltd.	P1	C (37)
Dptx3186 Neoplasm	Dewpoint Therapeutics	P1	C (37)
ds-2243a Neoplasm	Daiichi Sankyo	P1	C (37)
ds3610a Neoplasm	Daiichi Sankyo	P1	C (37)
Eftilagimod Alfa Neoplasm	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	P1	C (37)
Egfr/B7H3 Car-T Neoplasm	National Cancer Institute (NCI)	P1	C (37)
Etc-159 Neoplasm	EDDC (Experimental Drug Development Centre), A*STAR Research Entities	P1	C (37)
ftl008.16 Neoplasm	Sound Biopharmaceuticals Ltd.	P1	C (37)
FXB0871 Neoplasm	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	P1	C (37)
gen1106 Neoplasm	Genmab	P1	C (37)
gk01 Neoplasm	Tianjin Medical University Cancer Institute and Hospital	P1	C (37)
gs-9911 Neoplasm	Gilead Sciences	P1	C (37)
gsk5733584 Neoplasm	GlaxoSmithKline	P1	C (37)

Showing 126 to 150 of 197 assets